Lockheed Martin Unveils Lower-Cost Patriot ACE Interceptor to Meet Rising Air Defense Demand 
Cathay Pacific Sees H1 Profit Surge on Strong Travel Demand 
Super Micro Computer Stock Jumps 20% After Record AI Orders and Margin Surge 
Samsung Cuts U.S. Consumer Electronics Jobs as Headquarters Moves to Texas 
Morgan Stanley Downgrades Adobe, Workday as AI Transition Raises Growth Concerns 
SpaceX Q2 Earnings on Aug. 4 Set Stage for Historic Insider Share Unlock 
Amkor Stock Surges 17% After $1.5 Billion Nvidia AI Packaging Partnership 
GE Vernova Q2 Revenue Tops Estimates as Earnings Miss, Shares Slide Despite Higher 2026 Outlook 
Intel, AMD Seek Long-Term China Server CPU Deals as AI Demand Drives Supply Crunch 
Judge Approves Anthropic’s $1.5 Billion AI Copyright Settlement With Authors 
Wistron Opens $700M Texas AI Factory to Build Nvidia GB300 Superchips 
Nike Shifts China Online Sales Strategy to Boost Brand and Fight Local Rivals 
Wistron Opens $700M Texas AI Factory to Build Nvidia Superchips in U.S. 
KPMG Australia Appoints John Sams as CEO Following Audit Leak Scandal 
Nvidia Reveals 9.3% Stake in AI Cloud Firm Nebius Following $2 Billion Investment 
Trump Administration Monitors OpenAI Incident as Lawmakers Push AI Kill Switch Bill 
Reckitt Benckiser is considering the sale of its subsidiary, Mead Johnson Nutritionals, which is based in China. It was said that the British multinational consumer goods company is eyeing at least $2 billion for the deal.
Sources who have knowledge on the matter told Reuters that Reckitt Benckiser already hired the American financial services company, Morgan Stanley, to review its Mead Johnson infant formula unit in Greater China. The insiders were not names since the information shared is confidential.
The plans for the sale of Mead Johnson’s infant formula
Based on the report, Reckitt Benckiser could commence the sale process any time within the second quarter of this year. As soon as the bank receives feedback or recommendation from potential buyers, the sale will begin.
Then again, all the interested parties have been warned that Reckitt Benckiser has not made any definite decision yet, and business valuation could still change because of the negative effects of the COVID-19 pandemic. Moreover, in February, it was said that the company is exploring its other options on how to handle Mead Johnson’s infant formula unit.
In any case, Reckitt Benckiser acquired Mead Johnson in 2017 for $16.6 billion in 2017. The infant formula-maker gave the company billions from the sale of its leading milk brands that include Lactum, Enfapro, and Enfamil.
Why Mead Johnson is being sold
Reckitt Benckiser’s chief executive officer, Laxman Narasimhan, said that there is a big decline in sales in China which makes up 6 percent of the group sales. The reason for the dive is the closure of the Hong Kong border that is taking a long time to re-open due to coronavirus.
Also, the birth rate in one of the most populous countries in the world has gone down as well, so there is less infant to feed with the formula from Mead Johnson. Lastly, Chinese locals have been choosing to buy imported milk due to the 2008 milk contamination controversy scandal. In fact, it was noted that on China’s leading e-commerce platform, JD.Com, the top four best-selling brands of infant formula are all from foreign labels.
